Meta Biomed Statistics
Total Valuation
Meta Biomed has a market cap or net worth of KRW 81.08 billion. The enterprise value is 92.22 billion.
Market Cap | 81.08B |
Enterprise Value | 92.22B |
Important Dates
The next estimated earnings date is Thursday, March 20, 2025.
Earnings Date | Mar 20, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Meta Biomed has 22.87 million shares outstanding. The number of shares has increased by 56.31% in one year.
Current Share Class | n/a |
Shares Outstanding | 22.87M |
Shares Change (YoY) | +56.31% |
Shares Change (QoQ) | -58.51% |
Owned by Insiders (%) | 25.42% |
Owned by Institutions (%) | 7.09% |
Float | 17.06M |
Valuation Ratios
The trailing PE ratio is 8.83.
PE Ratio | 8.83 |
Forward PE | n/a |
PS Ratio | 0.88 |
PB Ratio | 0.97 |
P/TBV Ratio | 0.99 |
P/FCF Ratio | 13.43 |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.54, with an EV/FCF ratio of 15.28.
EV / Earnings | 6.01 |
EV / Sales | 1.00 |
EV / EBITDA | 5.54 |
EV / EBIT | 7.70 |
EV / FCF | 15.28 |
Financial Position
The company has a current ratio of 1.18, with a Debt / Equity ratio of 0.67.
Current Ratio | 1.18 |
Quick Ratio | 0.87 |
Debt / Equity | 0.67 |
Debt / EBITDA | 3.45 |
Debt / FCF | 9.50 |
Interest Coverage | 3.62 |
Financial Efficiency
Return on equity (ROE) is 19.14% and return on invested capital (ROIC) is 5.75%.
Return on Equity (ROE) | 19.14% |
Return on Assets (ROA) | 4.99% |
Return on Capital (ROIC) | 5.75% |
Revenue Per Employee | 340.59M |
Profits Per Employee | 56.62M |
Employee Count | 271 |
Asset Turnover | 0.62 |
Inventory Turnover | 3.30 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.16% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -14.16% |
50-Day Moving Average | 3,791.70 |
200-Day Moving Average | 4,273.85 |
Relative Strength Index (RSI) | 44.48 |
Average Volume (20 Days) | 227,770 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Meta Biomed had revenue of KRW 92.30 billion and earned 15.34 billion in profits. Earnings per share was 405.80.
Revenue | 92.30B |
Gross Profit | 42.51B |
Operating Income | 11.98B |
Pretax Income | 11.17B |
Net Income | 15.34B |
EBITDA | 16.63B |
EBIT | 11.98B |
Earnings Per Share (EPS) | 405.80 |
Balance Sheet
The company has 48.80 billion in cash and 57.36 billion in debt, giving a net cash position of -8.56 billion or -374.20 per share.
Cash & Cash Equivalents | 48.80B |
Total Debt | 57.36B |
Net Cash | -8.56B |
Net Cash Per Share | -374.20 |
Equity (Book Value) | 85.97B |
Book Value Per Share | 3,645.66 |
Working Capital | 12.84B |
Cash Flow
In the last 12 months, operating cash flow was 17.91 billion and capital expenditures -11.88 billion, giving a free cash flow of 6.04 billion.
Operating Cash Flow | 17.91B |
Capital Expenditures | -11.88B |
Free Cash Flow | 6.04B |
FCF Per Share | 263.91 |
Margins
Gross margin is 46.06%, with operating and profit margins of 12.98% and 16.62%.
Gross Margin | 46.06% |
Operating Margin | 12.98% |
Pretax Margin | 12.10% |
Profit Margin | 16.62% |
EBITDA Margin | 18.02% |
EBIT Margin | 12.98% |
FCF Margin | 6.54% |
Dividends & Yields
This stock pays an annual dividend of 20.00, which amounts to a dividend yield of 0.56%.
Dividend Per Share | 20.00 |
Dividend Yield | 0.56% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | 2.98% |
Buyback Yield | -56.31% |
Shareholder Yield | -55.75% |
Earnings Yield | 11.45% |
FCF Yield | 7.44% |
Stock Splits
The last stock split was on April 23, 2010. It was a forward split with a ratio of 2.
Last Split Date | Apr 23, 2010 |
Split Type | Forward |
Split Ratio | 2 |
Scores
Meta Biomed has an Altman Z-Score of 1.89. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.89 |
Piotroski F-Score | n/a |